Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

Development of hyperdiploidy starts at an early age and takes a decade to complete

Mehmet K. Samur, Anil Aktas Samur, Parth Shah, Joseph Park, Mariateresa Fulciniti, Masood A Shammas, Jill Corre, Kenneth C. Anderson, Giovanni Parmigiani, Hervé Avet-Loiseau, Nikhil C. Munshi

Blood blood.2024025250.

https://doi.org/10.1182/blood.2024025250

Published: 2024

Includes: Supplemental data

Journal Articles

CRISPR-Based Functional Transcriptomics Defines the Tumor-Dependency and Molecular Determinants of Long Noncoding RNAs in Multiple Myeloma

Eugenio Morelli, Anil Aktas-Samur, Domenico Maisano, Claire Gao, Na Liu, Vanessa Favasuli, Marcello Turi, Pietro Folino, Mariateresa Fulciniti, Annamaria Gulla, Kenneth C. Anderson, Mehmet K. Samur, Nikhil C Munshi

Blood (2023) 142 (Supplement 1): 640.

https://doi.org/10.1182/blood-2023-185523

Published: 2023

Journal Articles

Venetoclax Resistance Results in Broad Resistance to Majority of Anti-MM Agents Due to the Suppression of Apoptosis but Can be Overcome By BCMA-Targeted Immunotherapy

Mariateresa Fulciniti, Shuhui Deng, Sanika Dereibal, Vera Joy Weiler, Madhumouli Chatterjee, Jessica Ng Fong, Chandraditya Chakraborty, Rao Prabhala, Masood A. Shammas, Anil Aktas-Samur, Mehmet K. Samur, Annamaria Gulla, Kenneth C. Anderson, Nikhil C Munshi

Blood (2023) 142 (Supplement 1): 3311.

https://doi.org/10.1182/blood-2023-187374

Published: 2023

Journal Articles

High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma

Mehmet Kemal Samur, Marco Roncador, Anil Aktas Samur, Mariateresa Fulciniti, Abdul Hamid Bazarbachi, Raphael Szalat, Masood A. Shammas, Adam S. Sperling, Paul G. Richardson, Florence Magrangeas, Stephane Minvielle, Aurore Perrot, Jill Corre, Philippe Moreau, Anjan Thakurta, Giovanni Parmigiani, Kenneth C. Anderson, Hervé Avet-Loiseau, Nikhil C. Munshi

Blood (2023) 141 (14): 1724–1736.

https://doi.org/10.1182/blood.2022017094

Published: 2023

Includes: Supplemental data

Journal Articles

A MIR17HG-derived long noncoding RNA provides an essential chromatin scaffold for protein interaction and myeloma growth

Blood (2023) 141 (4): 391–405.

https://doi.org/10.1182/blood.2022016892

Published: 2023

Includes: Supplemental data

Journal Articles

Bioprocessing of MIR17HG Results in Long and Short Noncoding RNAs with Targetable Tumor-Promoting Activity in Multiple Myeloma

Blood (2022) 140 (Supplement 1): 1551–1552.

https://doi.org/10.1182/blood-2022-167604

Published: 2022

Journal Articles

Somatic Changes Prior to the Development of Hyperdiploidy Expose Mutation Accumulation Rate and Activated Processes in Multiple Myeloma

Thomas C. Smits, Anil Aktas-Samur, Romain Lannes, Mariateresa Fulciniti, Masood A. Shammas, Jill Corre, Giovanni Parmigiani, Herve Avet-Loiseau, Nikhil C Munshi, Mehmet K. Samur

Blood (2022) 140 (Supplement 1): 7062–7063.

https://doi.org/10.1182/blood-2022-168837

Published: 2022

Journal Articles

Long Noncoding RNA LINC01410 Interacts with the Minichromosome Maintenance (MCM) Complex to Promote Tumor Cell Growth in Multiple Myeloma

Doriana Gramegna, Na Liu, Yao Yao, Megan Johnstone, Domenico Maisano, Annamaria Gulla, Anil Aktas-Samur, Aldo Roccaro, Mehmet K. Samur, Mariateresa Fulciniti, Eugenio Morelli, Nikhil C Munshi

Blood (2022) 140 (Supplement 1): 4191–4192.

https://doi.org/10.1182/blood-2022-169185

Published: 2022

Journal Articles

In Multiple Myeloma Patients without Known Cytogenetic Risk Features, Genomic Features Contribute to Early Death Risk at Diagnosis

Anil Aktas-Samur, Jill Corre, Laure Buisson, Mariateresa Fulciniti, Kenneth C. Anderson, Mehmet K. Samur, Nikhil C Munshi, Herve Avet-Loiseau

Blood (2022) 140 (Supplement 1): 4362–4363.

https://doi.org/10.1182/blood-2022-168943

Published: 2022

Journal Articles

Differences in Single Cells between BCMA-Targeting CAR T-Cell Therapy Responders and Non-Responders Reveals Initial Resistance and Acquired Resistance Are Driven By Different Factors

Mehmet K. Samur, Nathan Martin, Ethan Thompson, Mariateresa Fulciniti, Anil Aktas-Samur, Shari Kaiser, Nikhil C Munshi

Blood (2022) 140 (Supplement 1): 2106–2107.

https://doi.org/10.1182/blood-2022-168903

Published: 2022

Journal Articles

IgM-MM is predominantly a pre–germinal center disorder and has a distinct genomic and transcriptomic signature from WM

Abdul Hamid Bazarbachi, Hervé Avet-Loiseau, Raphael Szalat, Anil Aktas Samur, Zachary Hunter, Masood Shammas, Jill Corre, Mariateresa Fulciniti, Kenneth C. Anderson, Giovanni Parmigiani, Steven P. Treon, Mohamad Mohty, Nikhil C. Munshi, Mehmet Kemal Samur

Blood (2021) 138 (20): 1980–1985.

https://doi.org/10.1182/blood.2021011452

Published: 2021

Includes: Supplemental data

Journal Articles

Identifying Long Noncoding RNA Dependencies Using CRISPR Interference (CRISPRi)-Based Platform in Multiple Myeloma

Blood (2021) 138 (Supplement 1): 894.

https://doi.org/10.1182/blood-2021-151705

Published: 2021

Journal Articles

Defining Genomic Probability of Progression to Identify Low-Risk Smoldering Multiple Myeloma

Anil Aktas-Samur, Mariateresa Fulciniti, Sanika Derebail, Raphael Szalat, Giovanni Parmigiani, Jill Corre, Herve Avet-Loiseau, Mehmet K. Samur, Nikhil C. Munshi

Blood (2021) 138 (Supplement 1): 545.

https://doi.org/10.1182/blood-2021-152317

Published: 2021

Journal Articles

Decreasing Costs and Clinic Wait Time While Maintaining Safety for Patients Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) for Multiple Myeloma

Eno Inyang, Anil Aktas-Samur, Nikhil C. Munshi, Houry Leblebjian

Blood (2021) 138 (Supplement 1): 666.

https://doi.org/10.1182/blood-2021-146605

Published: 2021

Journal Articles

Dual BCL-2/BCL-XL Inhibitor Pelcitoclax (APG-1252) Overcomes Intrinsic and Acquired Resistance to Venetoclax in Multiple Myeloma Cells

Leona Yamamoto, Sanika Derebail, Anil Aktas-Samur, Teru Hideshima, Zuzana Chyra, Chandraditya Chakraborty, Yao Yao, Doriana Gramegna, Eugenio Morelli, Mehmet K. Samur, Jing Deng, Yifan Zhai, Annamaria Gulla, Mariateresa Fulciniti, Kenneth C. Anderson, Nikhil C. Munshi

Blood (2021) 138 (Supplement 1): 2655.

https://doi.org/10.1182/blood-2021-149530

Published: 2021

Journal Articles

B Cell Transcriptional Coactivator POU2AF1 (BOB-1) Is an Early Transcription Factor Modulating the Protein Synthesis and Ribosomal Biogenesis in Multiple Myeloma: With Therapeutic Implication

Zuzana Chyra, Mehmet K. Samur, Anil Aktas-Samur, Yao Yao, Sanika Derebail, Tommaso Perini, Yan Xu, Eugenio Morelli, Sophia Adamia, Woojun D Park, Lin Charles, Ryosuke Shirasaki, Masood A. Shammas, Constantine S. Mitsiades, Roman Hajek, Mariateresa Fulciniti, Nikhil C. Munshi

Blood (2021) 138 (Supplement 1): 2670.

https://doi.org/10.1182/blood-2021-152121

Published: 2021

Journal Articles

Dysfunctional HDAC8 Impacts Genomic Integrity and Is a Novel Therapeutic Target in Multiple Myeloma

Zuzana Chyra, Srikanth Talluri, Rao Prabhala, Mehmet K. Samur, Anil Aktas-Samur, Yan Xu, Aaron B. Beeler, Roman Hajek, Mariateresa Fulciniti, Masood A. Shammas, Nikhil C. Munshi

Blood (2021) 138 (Supplement 1): 1610.

https://doi.org/10.1182/blood-2021-153382

Published: 2021

Journal Articles

16p Deletion Involving BCMA Locus Is Frequent and Predominantly Observed with del17p

Mehmet K. Samur, Anil Aktas-Samur, Romain Lannes, Jill Corre, Anjan Thakurta, Kenneth C. Anderson, Herve Avet-Loiseau, Nikhil C. Munshi

Blood (2021) 138 (Supplement 1): 1590.

https://doi.org/10.1182/blood-2021-152286

Published: 2021

Journal Articles

Presence of Extrachromosomal DNA (ecDNA) Impacts Both Progression Free and Overall Survival and Is an Independent Poor Prognostic Marker in Multiple Myeloma

Parth Shah, Anil Aktas-Samur, Mariateresa Fulciniti, Raphael Szalat, Masood A. Shammas, Paul G. Richardson, Florence Magrangeas, Stephane Minvielle, Aurore Perrot, Jill Corre, Philippe Moreau, Anjan Thakurta, Kenneth C. Anderson, Herve Avet-Loiseau, Nikhil C. Munshi, Mehmet K. Samur

Blood (2021) 138 (Supplement 1): 461.

https://doi.org/10.1182/blood-2021-151647

Published: 2021

Journal Articles

Continuous Pre-Dose Assessment of Laboratory Parameters Is Not Required for Multiple Myeloma Patients Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD)

Eno Inyang, PharmD, BCPS, Nikhil C. Munshi, MD, Anil Aktas-Samur, PhD, Houry Leblebjian, PharmD, BCOP

Blood (2020) 136 (Supplement 1): 11.

https://doi.org/10.1182/blood-2020-136342

Published: 2020

NARROW

Development of hyperdiploidy starts at an early age and takes a decade to complete

CRISPR-Based Functional Transcriptomics Defines the Tumor-Dependency and Molecular Determinants of Long Noncoding RNAs in Multiple Myeloma

Venetoclax Resistance Results in Broad Resistance to Majority of Anti-MM Agents Due to the Suppression of Apoptosis but Can be Overcome By BCMA-Targeted Immunotherapy

High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma

A MIR17HG-derived long noncoding RNA provides an essential chromatin scaffold for protein interaction and myeloma growth

Bioprocessing of MIR17HG Results in Long and Short Noncoding RNAs with Targetable Tumor-Promoting Activity in Multiple Myeloma

Somatic Changes Prior to the Development of Hyperdiploidy Expose Mutation Accumulation Rate and Activated Processes in Multiple Myeloma

Long Noncoding RNA LINC01410 Interacts with the Minichromosome Maintenance (MCM) Complex to Promote Tumor Cell Growth in Multiple Myeloma

In Multiple Myeloma Patients without Known Cytogenetic Risk Features, Genomic Features Contribute to Early Death Risk at Diagnosis

Differences in Single Cells between BCMA-Targeting CAR T-Cell Therapy Responders and Non-Responders Reveals Initial Resistance and Acquired Resistance Are Driven By Different Factors

IgM-MM is predominantly a pre–germinal center disorder and has a distinct genomic and transcriptomic signature from WM

Identifying Long Noncoding RNA Dependencies Using CRISPR Interference (CRISPRi)-Based Platform in Multiple Myeloma

Defining Genomic Probability of Progression to Identify Low-Risk Smoldering Multiple Myeloma

Decreasing Costs and Clinic Wait Time While Maintaining Safety for Patients Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) for Multiple Myeloma

Dual BCL-2/BCL-XL Inhibitor Pelcitoclax (APG-1252) Overcomes Intrinsic and Acquired Resistance to Venetoclax in Multiple Myeloma Cells

B Cell Transcriptional Coactivator POU2AF1 (BOB-1) Is an Early Transcription Factor Modulating the Protein Synthesis and Ribosomal Biogenesis in Multiple Myeloma: With Therapeutic Implication

Dysfunctional HDAC8 Impacts Genomic Integrity and Is a Novel Therapeutic Target in Multiple Myeloma

16p Deletion Involving BCMA Locus Is Frequent and Predominantly Observed with del17p

Presence of Extrachromosomal DNA (ecDNA) Impacts Both Progression Free and Overall Survival and Is an Independent Poor Prognostic Marker in Multiple Myeloma

Continuous Pre-Dose Assessment of Laboratory Parameters Is Not Required for Multiple Myeloma Patients Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only